The Bavarian thromboembolie risk cohorts study (BATER);Die bayerische thromboembolierisiko-kohortenstudie (BATER)

Deutsche Medizinische Wochenschrift

Volumn 125, Issue 1-2, 2000, Pages 2-6

  Assmann, A ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Institut fur Pharmakoepidemiologie   (Germany)

^c Gesundheitsforschung Berlin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; VEIN THROMBOSIS;

EID: 0034614366     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1023875     Document Type: Article

References (24)

1. 1 Bertina, R. M., Koelman, B. P., T. Koster, F. R. Rosendaal, R. J. Dirven, H. de Ronde, P. A. van der Velden, P. H. Reitsam: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994), 64-67.
2. 2 Bloemenkamp, K. W. M., F. R. Rosendaal, F. M. Helmerhorst, H. R. Büller, J. P. Vandenbrouke: Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346 (1995), 1593-1596..
3. 3 Dahlbäck, B., M. Carlsson, P. J. Svensson: Familial Thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA 90 (1993), 1004-1008.
4. 4 Farmer, R. D. T., R. A. Lawrenson, C. R. Thompson, J. G. Kennedy, I. R. Hambleton: Population-based study of venous thromboembolism associated with various oral contraceptives. Lancet 349 (1997), 83-88.
5. 5 Farmer, R. D. T., T. D. Preston: The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J. Obstet. Gynaecol. 15 (1995), 195-200.
6. 6 Farmer, R. D. T., J. C. Todd, M. A. Lewis, K. D. MacRae, T. J. Williams : The risks of venous thromboembolic disease among German women using oral contraceptives: Contraception 57 (1998), 67-70.
7. 7 Gerstmann, B. B., J. M. Piper, D. K. Tomita. W. J. Ferguson, B. V. Stadel, F. E. Lundin: Oral contraceptive estrogen dose and the risk of thromboembolic disease. Am. J. Epidemiol. 133 (1991), 32-37.
8. 8 Heinemann, L. A. J., A. Assmann, M. Spannagl, W. Schramm, A. Dick, C. Kluft, M. P. M. de Maat: Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception 58 (1998), 321-322.
9. 9 Heinemann, L. A. J., E. Garbe: The third generation pill scare - an unfounded, non-causal artefact. Middle East Fert. Soc. J. 3 (1998), 29-34.
10. 10 Jick, H., S. S. Jick, V. Gurevich, M. W. Myers, C. Vasilakis: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346 (1995), 1589-1593.
11. 11 Koster, T., F. R. Rosendaal, H. de Ronde, E. Briet, J. P. Vandenbroukke, R. M. Bettina: Venous thrombosis due to poor anticoagulant response to activated protein C. Lancet 342 (1993), 1503-1506.
12. 12 Lewis, M. A., K. D. MacRae, D. Kühl-Habich: Venous thromboembolism, oral contraceptive use, and exposure history (abstract). Eur. J. Contraception Reprod. Health Care 3 (suppl. 1) (1998), 36.
13. 13 Lewis, M. A., W. O. Spitzer, L. A. J. Heinemann, K. D. MacRae, R. Bruppacher, M. Thorogood: Third generation oral contraceptives and risk of myocardial infarction. BMJ 312 (1996), 88-90.
14. 14 Lidegaard, O., B. Edström, S. Kreiner. Oral contraceptives and venous thromboembolism. Contraception 57 (1998), 291-301.
15. 15 Rosen, S. B., A. Sturk: Activated protein C resistance - a major risk factor for thrombosis. Eur. J. Clin. Chem. Clin. Biochem. 35 (1997), 501.
16. 16 Sharp, D. W.: Altered factor V explains one-fifth of venous thrombosis. Science Watch October (1995), 6.
17. 17 Spannagl, M., A. Dick, A. Assmann, L. Heinemann, W. Schramm: Resistance to activated protein C in women using oral contraceptives. Semin. Thromb. Hemost. 24 (1998), 423-430.
18. 18 Spitzer, W. O., M. A. Lewis, L. A. J. Heinemann, M. Thorogood, K. D. MacRae: Third generation oral contraceptives and risk of venous thromboembolic disorders an international case-control study. BMJ 312 (1996), 83-88.
19. 19 Suissa, S., L. Blair, W. O. Spitzer, J. Cosson, M. Lewis, L. A. J. Heinemann: First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception 56 (1997), 141-146.
20. 20 Svensson, P. J., B. Dahlbäck: Resistance to activated protein C as a basis for venous thrombosis. New Engl. J. Med. 330 (1994), 517-522.
21. 21 Szucs, T., W. Schramm: Public health economic evaluation of screening for APC resistance (Leiden mutation) in new oral contraceptive users. Med. Klin. 91 (1996), 317-319.
22. 22 Vessey, M., D. Mant, A. Smith, D. Yeates: Oral contraceptives and venous thromboembolism.Brit. Med. J. 292 (1986), 526.
23. 23 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 346 (1995), 1575-1581.
24. 24 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Effect of different progestagens in low estrogen oral contraceptives on venous thromboembolic disease. Lancet 346 (1995), 1582-1588.